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Renal Handling of Galectin-3 in the General Population, Chronic Heart
Failure, and Hemodialysis
Wouter C. Meijers, MD; A. Rogier van der Velde, MD; Willem P. Ruifrok, MD, PhD; Nicolas F. Schroten, MD; Martin M. Dokter, BSc;
Kevin Damman, MD, PhD; Solmaz Assa, MD; Casper F. Franssen, MD, PhD; Ron T. Gansevoort, MD, PhD; Wiek H. van Gilst, PhD;
Herman H. Sillje, PhD; Rudolf A. de Boer, MD, PhD
Background-—Galectin-3 is a biomarker for prognostication and risk stratiﬁcation of patients with heart failure (HF). It has been
suggested that renal function strongly relates to galectin-3 levels. We aimed to describe galectin-3 renal handling in HF.
Methods and Results-—In Sprague–Dawley rats, we infused galectin-3 and studied distribution and renal clearance. Furthermore,
galectin-3 was measured in urine and plasma of healthy controls, HF patients and hemodialysis patients. To mimic the human
situation, we measured galectin-3 before and after the artiﬁcial kidney. Infusion in rats resulted in a clear increase in plasma and
urine galectin-3. Plasma galectin-3 in HF patients (n=101; mean age 64 years; 93% male) was signiﬁcantly higher compared to
control subjects (n=20; mean age 58 years; 75% male) (16.6 ng/mL versus 9.7 ng/mL, P<0.001), while urinary galectin-3 in HF
patients was comparable (28.1 ng/mL versus 35.1 ng/mL, P=0.830). The calculated galectin-3 excretion rate was lower in HF
patient (2.3 mL/min [1.5 to 3.4] versus 3.9 mL/min [2.3 to 6.4] in control subjects; P=0.005). This corresponded with a
signiﬁcantly lower fractional excretion of galectin-3 in HF patients (2.4% [1.7 to 3.7] versus 3.0% [1.9 to 5.5]; P=0.018). These
differences, however, were no longer signiﬁcant after correction for age, gender, diabetes, and smoking. HF patients who received
diuretics (49%) showed signiﬁcantly higher aldosterone and galectin-3 levels. Hemodialysis patients (n=105; mean age 63 years;
65% male), without urinary galectin-3 excretion, had strongly increased median plasma galectin-3 levels (70.6 ng/mL).
Conclusions-—In this small cross-sectional study, we report that urine levels of galectin-3 are not increased in HF patients, despite
substantially increased plasma galectin-3 levels. The impaired renal handling of galectin-3 in patients with HF may explain the
described relation between renal function and galectin-3 and may account for the elevated plasma galectin-3 in HF. ( J Am Heart
Assoc. 2014;3:e000962 doi: 10.1161/JAHA.114.000962)
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G alectin-3 is a galactosidase-binding lectin that is able tobind complex carbohydrates.1–3 In the heart, galectin-3
is secreted by activated macrophages and binds several
matricellular proteins such as laminin, ﬁbronectin, and
collagens. When ligand-bound, galectin-3 forms interstitial
conjugates, which are thought to contribute to myocardial
stiffness and cardiac dysfunction.4,5 Galectin-3 is an emerging
biomarker for prognostication and risk stratiﬁcation of
patients with acute and chronic heart failure (HF).4,6,7 The
most recent American College of Cardiology/American Heart
Association guidelines provided a level IIB recommendation
for the use of galectin-3 in risk stratiﬁcation.8 In experimental
models of HF, myocardial transcription and translation of
galectin-3 has been reported,9,10 and it is assumed that
increased circulating levels of galectin-3 in HF may be
explained by excess cardiac production. In human subjects,
galectin-3 can be measured in plasma using an established
ELISA.11 Circulating levels of galectin-3 are in the 10 to
13 ng/mL range in the general population,11–13 but are
substantially increased in HF,14–17 rising to 15 to 30 ng/mL,
depending on the severity of HF and the presence of
comorbidities, speciﬁcally kidney disease, as galectin-3 levels
in HF have a strong relation with renal function.16,18 Both in
the general population12 and in patients with HF,16,18,19
decreased renal function is among the strongest correlates of
increased circulating galectin-3. It has also been observed
that galectin-3 levels precede the development of chronic
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kidney disease.20 Thus, renal function is an important factor
to take into account in the interpretation of a given value of
galectin-3. Renal handling of galectin-3 may be altered in
patients with HF, a phenomenon that has been described for
other biomarkers such as N-terminal-pro brain natriuretic
peptide (NT-proBNP) and neutrophil gelatinase-associated
lipocalin.21,22 We hypothesized that renal handling of galec-
tin-3 would be different in HF compared to healthy subjects.
We studied this in a rat model, and by measuring plasma and
urinary galectin-3 in a well-characterized cohort of 101
chronic HF patients, comparing them to 20 control subjects
and 105 hemodialysis (HD) patients.
Methods
Experimental Studies of Galectin-3 Clearance
Recombinant galectin-3 production
Human recombinant galectin-3 was produced by Escherichia
coli (BL21[DE3] RIL) containing a speciﬁc plasmid (pet28b)
encoding human full-length galectin-3. Recombinant galectin-
3 was collected and puriﬁed via binding to a-lactose-agarose
beads (Sigma-Aldrich). The purity of the obtained protein was
studied by SDS-PAGE followed by Coomassie blue staining
and Western blot to exclude any contamination or protein
degradation. We removed endotoxins via a column method
(ActiClean Etox; Sterogene bioseparations, USA); in our
experiments, the endotoxin levels were kept below 10 EU/
mg. Quality control–endotoxin contamination was routinely
checked by LAL assay (Lonza).
Animal studies
Animals were housed under standard conditions. All animal
studies were approved by the Animal Ethical Committee of the
University of Groningen, The Netherlands, and conducted in
accordance with existing European Commission guidelines for
the care and use of laboratory animals (reference number
6474).
First, we conducted an acute experiment, where we
intravenously injected either a bolus of human recombinant
galectin-3 or saline in Sprague–Dawley rats (n=3/group).
After infusion, we sampled blood at different time points over
a period of 24 hours. Blood samples were centrifuged for
10 minutes at 2000g within 1 hour after collection, and
plasma was obtained to measure levels of galectin-3. The
results were used to calculate the clearance and the volume
of distribution of galectin-3 in rats by Iterative Bayesian 2-
Stage analysis using the program MultiFit (written by J.H.
Proost).23 These calculations were performed to estimate the
continuous infusion rate of galectin-3 resulting in a steady-
state plasma level of 25 ng/mL during long-term infusion.
Lastly, we conducted a long-term experiment of galectin-3
infusion to assess the effects of chronic galectin-3 clearance
in healthy animals. An osmotic minipump (Alzet, Cupertino
CA, type 2ML4) ﬁlled with either recombinant galectin-3 or
saline was implanted intraperitoneally in Sprague–Dawley
rats. After 4 days, we sampled blood and started to collect
24-hour urine. The plasma and urine galectin-3 concentrations
were measured on both samples (control n=3; galectin-3
infusion n=3). Inhalation of isoﬂurane 2% was used for all of
the anesthesia throughout the study.
Patient Populations
We analyzed baseline plasma and urine samples from 3
cohorts: (1) 101 stable chronic HF patients; (2) 105 stable
patients with end-stage renal disease who were on HD; and
(3) 20 control subjects. The HF patient cohort has been
described in detail previously (Clinical trial identiﬁer NC
T01092130).24 In brief, 101 HF patients ≥18 years of age and
a left ventricular ejection fraction <45% were included, who
received optimal HF medication (including angiotensin-
converting enzyme inhibitor [ACEi] or angiotensin receptor
blocker, b-blocker, and mineralocorticoid-receptor antagonist,
when indicated), and randomized to vitamin D (2000 IU daily)
or control for 6 weeks. The HD patient cohort has also been
described in detail elsewhere.25 These patients received HD
for at least 3 months on a 3-time-per-week schedule and had
a left ventricular ejection fraction of 50% (10). Additionally,
20 healthy subjects were randomly selected from a large
population cohort12 and served as controls. Healthy was
deﬁned as the absence of the self-reported cardiovascular
disease or cancer, and currently not being prescribed
medication.
These studies and the current analyses have been
performed to conform with the Declaration of Helsinki; all 3
study protocols were reviewed and approved by the local
Institutional Review Board, and all study subjects provided
written informed consent.
Biochemical Measurements
Hematology, chemistry, and urinalysis were performed by
routine clinical chemistry on the day of the visit. Blood of the
HD patients was drawn prior to hemodialysis after a period of
2 days prior to HD treatment. Plasma and urine galectin-3
levels were determined by an ELISA developed by BG
Medicine (Galectin-3 assayTM, BG Medicine, Inc., Waltham,
USA). This assay is US Food and Drug Administration
approved, and has a high sensitivity (lower limit of detection
1.13 ng/mL) and has no cross-reactivity with collagens
or other members of the galectin family. Calibration of
the assay was performed according to the manufacturer’s
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recommendation and values were normalized to a standard
curve.11 Commonly used medication such as ACEi, b-block-
ers, aldosterone antagonist, diuretics, acetylsalicylic acid,
warfarin, coumarines, and digoxin have no interference
with the assay. Two standard controls were included in all
plasma runs: a lower control (expected value 13.0 to
23.1 ng/mL) and an upper control (expected value 48.9 to
81.5 ng/mL). The average lower control values were
21.90.65 ng/mL, and the average upper control values
were 71.31.33 ng/mL. We observed in our plasma control
samples an intravariability in coefﬁcient of variation of 6.3%
and an intervariability in coefﬁcient of variation of 2.4%.
Plasma aldosterone concentration was measured using an
ELISA kit (Alpco, Salem, NH) and the results are reported in
pg/mL. The lower detection limit was 10 pg/mL. Intra-assay
precision has been reported as 6.6% and interassay precision
has been reported as 9.6%.26
Renal Galectin-3 Parameters
Twenty-four-hour urine was collected from all HF patients and
control subjects. We calculated creatinine clearance
(expressed as mL/min) using the formula: ((Ucreat9Vurine)/
Pcreat), where Ucreat stands for urine creatinine concentration,
Vurine for 24-hour urinary volume, and Pcreat for plasma
creatinine concentration. This value is used as the glomerular
ﬁltration rate (GFR). We also calculated estimated GFR with
the simpliﬁed modiﬁcation of diet in renal disease formula and
the chronic kidney disease-epidemiology formula,27 to assess
whether the use of different formulae would alter the study
results. Creatinine clearance of HD patients was by deﬁnition
0 mL/min, because these patients were anuric. We expressed
urine galectin-3 concentrations as per gram urinary creatinine
to account for differences in concentration due to urine
dilution or concentration.
Various calculation methods to assess different stages in
the ﬁltration process of the kidney were used. These methods
have previously been used by our department regarding NT-
proBNP.21 The theoretical amount of freely ﬁltered galectin-3
by the glomerulus to the tubules was calculated by:
GFR9Pgalectin-3 (=ﬁltered load, expressed as lg/24 hours).
The actual urinary galectin-3 excretion was calculated as:
Ugalectin-39Vurine (expressed as lg/24 hours). The renal
clearance of galectin-3 was calculated as: ((Ugalectin-39Vurine)/
Pgalectin-3 (expressed as mL/min). To examine the proportion
of the ﬁltered load that was excreted, we calculated the
fractional galectin-3 clearance: (renal clearance of galectin-3/
GFR)9100%.
Since it has been reported that aldosterone is closely linked
with galectin-3,28 and aldosterone antagonists play a central
role in treatment of HF,29 we evaluated whether plasma
aldosterone modulates the renal handling of galectin-3 in HF.
Galectin-3 Levels Before and After the Dialyzer
To provide further clariﬁcation of the percentage of galectin-3
ﬁltered by the kidney, we conducted an experiment using
bicarbonate hemodialysis with a low-ﬂux polysulfone hollow-
ﬁber dialyzer (F8; Fresenius Medical Care) during a standard
HD session after a 2-day break of HD treatment. Two different
samples were taken from 16 HD patients after 30 minutes of
hemodialysis: (1) unﬁltered blood ﬂowing towards the artiﬁcial
kidney; and (2) ﬁltered blood immediately after the artiﬁcial
kidney, in which galectin-3 and creatinine concentrations
were measured.
Statistical Analyses
Continuous variables with a normal distribution are expressed
as meansSEM. Nominal variables are expressed as n
(%).Variables that are not normally distributed are expressed
as medians with interquartile ranges. Galectin-3 levels were
correlated with other variables using Spearman’s rank corre-
lation coefﬁcient. Data with a normal distribution were
compared with Student t tests, while data with skewed
distribution were compared by means of the Mann–Whitney U
tests, and categorical clinical variables were compared with
the Fisher exact test. One-way ANOVA was performed to
analyze differences for multiple-group comparisons, followed
by Bonferroni post hoc analysis. Analysis on repeated
measurements was performed using the Student paired 2-
tailed t test. All reported P values are 2-tailed, and values of
P<0.05 were considered statistically signiﬁcant. Analyses
were performed with Statistical Package for Social Sciences
software (SPSS version 20.0.0.1 for Windows, SPPS Inc,
Chicago, IL). The authors had full access to and take full
responsibility for the integrity of the data.
Results
Galectin-3 Clearance Experiment
We ﬁrst ascertained that the US Food and Drug Administra-
tion–approved ELISA detected human recombinant galectin-3,
whereas it should not detect endogenous rat galectin-3, thus
allowing reliable detection of the infused recombinant human
galectin-3 in rats. The course of plasma galectin-3 concen-
tration in rats over a period of 24 hours after an intravenous
bolus infusion of human recombinant galectin-3 is displayed
in Figure 1A. We did not detect any human recombinant
galectin-3 in the plasma of saline-infused rats. On the basis of
these results, we determined that galectin-3 plasma clearance
is 0.92 mL/min with a volume of distribution of 90 mL. We
then conducted an experiment in which we infused human
recombinant galectin-3 continuously for the duration of
DOI: 10.1161/JAHA.114.000962 Journal of the American Heart Association 3






















4 days. After 4 days, steady-state galectin-3 levels were 23.1
(4.9) ng/mL. The mean concentration of galectin-3 mea-
sured in 24-hour urine was 27.2 (8.1) ng/mL (Figure 1B).
From these experiments, we conclude that galectin-3 can be
cleared by the kidney, albeit incompletely. We controlled for
purity with Coomassie blue staining and Western blot staining
regarding the infused recombinant human galectin-3 (Fig-
ure 1C).
Patient Populations
Baseline characteristics of the HF patients, HD patients, and
control subjects are presented in Table 1. The healthy controls
differed substantially and signiﬁcantly fromHF andHD patients,
with respect to coefﬁcient of variation risk factors such as
smoking and diabetes, the use of medication, and biochemical
variables. Overall, the mean age of all study participants was
between 55 and 75 years and 60% were male. The HF patients
were mostly categorized in New York Heart Association class II
(90%) and had a mean left ventricular ejection fraction of
35% (8). All HF patients received background therapy
according to the current European Society of Cardiology
guidelines: ACE-i/angiotensin receptor blocker: n=101 (100%),
b–blockers: n=98 (97%), mineralocorticoid-receptor antago-
nists: n=29 (29%), and diuretics (mostly furosemide): n=49
(49%). The HD patients received ACEi/angiotensin receptor
blocker (n=10, 9.5%) and b-blockers (n=60, 57%). By protocol,
the control subjects received no medication. GFR was signif-
icantly lower in HF patients compared to controls (96 versus
124 mL/min; P=0.002).
Renal Handling
Plasma galectin-3 in HF patients was signiﬁcantly higher
compared to control subjects (16.6 ng/mL [14.5 to 19.3]
versus 9.7 ng/mL [8.9 to 12.4], respectively, P<0.001). In
contrast, the median urine galectin-3 levels in HF patients
were similar to controls (28.1 ng/mL [19.7 to 49.5] in
controls versus 35.1 ng/mL [21.2 to 50.3] in HF, P=0.830).
After correction for urinary creatinine, the difference in urine
galectin-3 remained nonsigniﬁcant (P=0.983, Figure 2). As a
consequence, the calculated renal galectin-3 clearance was
higher in control subjects compared to HF patients (3.9 mL/
min [2.3 to 6.4] versus 2.3 mL/min [1.5 to 3.4], P=0.005).
We observed that creatinine clearance was inversely corre-
lated with plasma galectin-3 levels in all subjects combined
(r=0.315, P=0.001). Fractional galectin-3 clearance was
signiﬁcantly lower in HF patients compared to the control
subjects (2.4% [1.7 to 3.7] versus 3.0% [1.9 to 5.5], P=0.018)
(Figure 3A and 3B) (Table 2). The same results were observed
when calculations were made with the simpliﬁed modiﬁcation
of diet in renal disease and the chronic kidney disease-
epidemiology formulas (not shown).
To address the issue of potential confounding, we
conducted further analyses. We analyzed the differences
between HF patients and controls by stepwise correcting for
age, diabetes, smoking status, and gender. We observed
that correction for these individual factors appears to
attenuate the numerical and statistical differences between
HF patients and controls; however, in all subanalyses we
always observed that in HF patients, plasma galectin-3 is
elevated, while urinary galectin-3 is not, resulting in
decreased galectin-3 clearance (Tables S1 through S7). A
ﬁnal analysis in which we corrected for age, gender,
diabetes, and smoking resulted in a comparison between
26 HF patients versus 15 healthy controls, shown in




Figure 1. Experimental data. A, Displays the galec-
tin-3 concentration over time after a single bolus IV
injection (3 rats/group; saline-infused rats are not
displayed because they did not show any recombi-
nant-human-galectin-3). B, Displays the plasma and
urine galectin-3 level of rats having received a
continuous infusion of galectin-3 via an osmotic
minipump (n=3); not signiﬁcant. C, Staining of
recombinant human galectin-3. CB indicates
Coomassie blue staining; WB, Western blot.
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galectin-3 remained elevated in HF patients, and urinary
galectin-3 was comparable between HF patients and
controls, while the difference in galectin-3 clearance and
fractional galectin-3 excretion was no longer signiﬁcant
between HF patients and controls.
All biochemical analyses were repeated 6 weeks after
baseline assessment to conﬁrm a steady state of galectin-3
handling, and we further examined whether renal clearance
could be based upon stratiﬁcation of GFR. These results are
presented in Figures 4 and 5. We observed a moderate
correlation between plasma aldosterone and plasma galectin-
3 levels in HF patients (r=0.360, P<0.001). Furthermore,
increased plasma aldosterone showed a signiﬁcant associa-
tion with lower urinary galectin-3 excretion (P=0.028;
r=0.311). Additionally, HF patients who received diuretics
(49%) had signiﬁcantly higher plasma aldosterone levels and
plasma galectin-3 levels; 44% of the patients on diuretics
showed both aldosterone and galectin-3 levels above median
(Figure 6).
In HD patients, who by deﬁnition have no galectin-3
clearance via the urine, we observed elevated plasma
galectin-3 levels before HD (median 70.6 ng/mL [54.0 to
88.3]) compared to plasma galectin-3 levels of HF patients
and healthy subjects (16.6 and 9.7 ng/mL, respectively).
Galectin-3 Filtration in HD Patients
To study whether galectin-3 could potentially be ﬁltered by
human glomeruli, we measured galectin-3 before and after a
Table 1. Baseline Characteristics of the Study Patients
Variables HF Patients (n=101) Hemodialysis Patients (n=105) Control Subjects (n=20) P Value
Age, y (mean, SD) 6410 6316 584 0.17
Male, n (%) 93 (93) 68 (65) 15 (75) 0.039
NYHA class, II/III 89/11 NA NA N/A
Diabetes mellitus, n (%) 14 (14) 23 (22) 0 <0.001
Current smoking, n (%) 22 (22) NA 0 <0.001
LVEF, % (mean, SD) 358 5010 NA <0.001
Systolic blood pressure, mm Hg (mean, SD) 11818 14125 11911 <0.001
Diastolic blood pressure, mm Hg (mean, SD) 7212 8118 718 <0.001
Serum creatinine, lmol/L (mean, SD) 9018 NA 7813 0.005
Creatinine clearance, mL/min (mean, SD) 9616 0 12411 <0.001
Plasma NGAL, ng/mL (mean, SD) 9374 NA 4340 0.004
Hematocrit, % (mean, SD) 434 354 414 <0.001
Medication
ACEi/ARB, n (% use) 101 (100) 10 (10) 0 <0.001
b-Blocker, n (% use) 98 (97) 60 (57) 0 <0.001
Loop diuretic, n (% use) 49 (49) 0 0 <0.001
Mineralocorticoid receptor antagonist, n (% use) 29 (29) NA 0 <0.001
ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HF, heart failure; LVEF, left ventricular ejection fraction; n, number of subjects;
NGAL, neutrophil gelatinase-associated lipocalin; NA, not available; N/A, not applicable; NYHA, New York Heart Association.
Figure 2. Plasma and urine galectin-3 concentrations in 3
different cohorts. Overview of the plasma and urine galectin-3
concentrations in the 3 cohorts (control [n=20], CHF [n=101], and
hemodialysis [n=105]). Data are displayed as medians with IQR.
Statistical test: Mann–Whitney U test. *P<0.05 control galectin-3
plasma compared to CHF galectin-3 plasma. **P<0.05 control
galectin-3 plasma compared to dialysis galectin-3 plasma.
#Hemodialysis patients were not obtained so no values could
be measured. CHF indicates chronic heart failure; IQR, interquar-
tile ranges.
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dialyzer. The median galectin-3 concentration of blood before
the artiﬁcial kidney was 49.7 ng/mL [33.2 to 60.4], while
after the dialyzer this was 34.3 [27.6 to 47.3] (26%);
P<0.001. To normalize our results, and obtain a reference, we
also measured creatinine in samples before (719263 lmol/
L) and after the dialyzer (16068 lmol/L (449%). We
conclude that galectin-3 can be ﬁltered by the dialyzer, albeit
at a lesser rate than creatinine (Figure 7).
Discussion
This study is the ﬁrst to describe that galectin-3 can be
measured in the urine of HF patients, and provides novel
insights in renal handling of galectin-3 in healthy and diseased
human subjects. Renal handling of galectin-3 appears to be
altered in HF, as plasma galectin-3 is clearly elevated, while
urinary levels are comparable to control subjects. As a
consequence, we demonstrate that fractional galectin-3
clearance is reduced in HF. HD patients, with no residual
clearance, showed strongly elevated plasma galectin-3 levels.
Although we clearly have to consider that differences between
the HF and HD patients and the controls may have
confounded our ﬁndings, these data shed new light on the
reported relation between renal function and plasma galectin-
3, and the altered renal handling of galectin-3 could explain, at
least in part, why galectin-3 accumulates in HF patients with
concomitant renal disease.
Galectin-3 is a relatively new biomarker that may be used
for risk stratiﬁcation in HF. However, several studies reported
that the predictive value of galectin-3 might be mitigated
when renal function is taken into account. Gopal et al.
analyzed the relation between estimated GFR and galectin-3
in control subjects and HF patients, both with preserved and
reduced ejection fraction, and showed that in HF patients,
levels of galectin-3 have a strong correlation with renal
function.18 However, these studies were descriptive only, and
it remains unclear whether galectin-3 elevations are a
consequence of renal function decline, or that rather the
elevated levels of galectin-3 themselves lead to further loss of
kidney function (and dysfunction of other organs, such as the
A
B
Figure 3. Renal handling of galectin-3. A, Shows the galectin-3
excretion rate difference between control subjects and heart
failure patients. B, Displays the difference in the proportion of
actually excreted galectin-3 in percentage between control
subjects and heart failure patients. *P<0.05 control subjects
compared to heart failure patients (n=20 vs n=101). Data are
displayed as medians with IQR. Statistical test: Mann–Whitney U
test. CHF indicates chronic heart failure; IQR, interquartile ranges.
Table 2. Parameters of Plasma and Urine Galectin-3
Variables HF Patients (n=101) Control Subjects (n=20) P Value
Plasma galectin-3, ng/mL 16.6 (14.5 to 19.3) 9.7 (8.9 to 12.4) <0.001
Urinary galectin-3, ng/mL 28.1 (19.7 to 49.5) 35.1 (21.2 to 50.3) 0.830
Urinary galectin-3, lg/g Cr 38.3 (27.9 to 65.5) 29.7 (19.3 to 79.1) 0.983
Urinary galectin-3, lg/24 h 51.4 (34.3 to 78.1) 47.5 (31.6 to 109.0) 0.958
Theoretical filtered load, lg/24 h 1543 (1228 to 1909) 1297 (839 to 1580) 0.016
Galectin-3 clearance, mL/min 2.3 (1.5 to 3.4) 3.9 (2.3 to 6.4) 0.005
Fractional galectin-3 excretion, % 2.4 (1.7 to 3.7) 3.0 (1.9 to 5.5) 0.018
Median values with (25th to 75th percentile). Cr indicates urinary creatinine.
DOI: 10.1161/JAHA.114.000962 Journal of the American Heart Association 6






















heart). The latter hypothesis is supported by observations in
the general population. de Boer et al. reported that plasma
galectin-3 bears a close relation with several parameters of
renal function, such as serum creatinine, estimated GFR, and
cystatin-C.12 In the Framingham Heart Study, galectin-3 was
shown to predict new-onset HF, and a recent article from the
same group reported that elevated plasma galectin-3 pre-
ceded the development of renal disease.20 From this, it has
been suggested that galectin-3 is not merely a marker of
disease, but rather may contribute to the development and
progression of heart and renal disease.4,12,13,20 Experimental
studies provided evidence that high levels of galectin-3 have
detrimental effects on the kidneys (ﬁbrosis and inﬂamma-
tion),30 and this also applies to the heart (ﬁbrosis, cardiac
dysfunction),10 the liver (ﬁbrosis),31 and the lungs (ﬁbrosis).32
Therefore, it is important to understand how galectin-3 is
regulated and handled, because sustained elevations may not
just be a marker for outcome, but may perpetuate disease
progression.
Renal dysfunction is very common in HF, and this is
accompanied by renal structural and functional changes that
have proven impact on the HF progression and prognosis.33
Our data suggest that renal function also affects galectin-3
handling in patients with HF. We speculate that reduced
renal clearance of galectin-3 may lead to accumulation of
plasma galectin-3 levels. The precise details of renal handling
are difﬁcult to study in human subjects. Due to the molecular
size of the galectin-3 molecule—around 27 kDa—it is
questionable whether galectin-3 is easily ﬁltered by the
glomeruli, but this could be facilitated by accurate folding of
the protein before ﬁltration. We have conducted several
experiments to study this. First, we infused human
recombinant galectin-3 in rats, and were able, once a steady
state developed after several days, to measure galectin-3
release in the urine. Second, we measured galectin-3 in
samples before and after HD, assuming that the dialyzer has
speciﬁcations with regard to galectin-3 that resemble the
physiological situation. We show that galectin-3 seemed to
be ﬁltered, however, far less than creatinine. However, given
the relatively high circulating levels—galectin-3 is about a
1000-fold more abundant than BNP—we would have
expected higher urinary levels of galectin-3 if the protein
would had been freely ﬁltered. We hypothesize that other
mechanisms must play a role. It may be that circulating
galectin-3 is bound to polysaccharides, which augments the
size of the complexes and thus further decreases free
ﬁltering. However, ancillary renal mechanisms likely play a
role also (for instance, reabsorption, tubular degradation, or
active tubular handling). We could speculate that renal injury
occurring in HF may attenuate adequate tubular reabsorp-
tion. However, calculated from the theoretical ﬁltered load,
we would have expected more galectin-3 to be present in
urine. To further elucidate this, further detailed mechanistic
studies will be required.
In general, urinary excretion and renal handling of
commonly used biomarkers in HF is an important topic of
interest. For instance, plasma and urinary NT-proBNP have
been measured before in control subjects, and a chronic HF
cohort and a decreased urinary concentration of NT-proBNP
was reported in chronic HF patients. The reduced urinary NT-
proBNP excretion was not related to concomitant impairment
of GFR, but was associated with impaired renal perfusion. It
was speculated that the reduced excretion could be related to
altered tubular handling.21
To provide further insights of correlates of urinary excre-
tion of galectin-3 in HF, we studied and identiﬁed an
interesting observation between galectin-3, plasma aldoste-
rone, and the use of diuretics. A close relationship between
Table 3. Parameters of Plasma and Urine Galectin-3 After Correction for Potential Confounders
Variables HF Patients (n=26) Control Subjects (n=15) P Value
Age, y (mean, SD) 584 574 0.462
Gender male, n (%) 26 (100) 15 (100) N/A
Diabetes, n (%) 0 (0) 0 (0) N/A
Smoking, n (%) 0 (0) 0 (0) N/A
Plasma galectin-3, ng/mL 15.1 (13.6 to 18.0) 9.7 (8.7 to 12.1) <0.001
Urinary galectin-3, ng/mL 28.0 (21.5 to 44.6) 39.7 (22.5 to 52.3) 0.376
Urinary galectin-3, lg/g Cr 34.4 (25.9 to 53.9) 53.3 (23.6 to 81.6) 0.347
Urinary galectin-3, lg/24 h 53.0 (31.7 to 90.5) 65.6 (37.4 to 115.9) 0.392
Theoretical filtered load, lg/24 h 1609 (1325 to 1915) 1164 (750 to 1529) 0.001
Galectin-3 clearance, mL/min 2.4 (1.4 to 3.9) 2.8 (2.0 to 5.7) 0.142
Fractional galectin-3 excretion, % 2.2 (1.6 to 3.2) 2.6 (1.0 to 4.8) 0.900
Median values with (25th to 75th percentile). Cr indicates urinary creatinine; HF, heart failure; N/A, not applicable.
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aldosterone and galectin-3 has been suggested in experimen-
tal studies.28 Chronic use of diuretics is accompanied by
reciprocal activation of the renin-angiotensin-aldosterone
system, and this leads to elevated circulating levels of
aldosterone.34 However, chronic use of diuretics has been
linked to progressive glomerulosclerosis and may not always
be of beneﬁt to the patient.35 Clearly, we cannot exclude that
the associations between the use of diuretics, elevated
aldosterone, and elevated galectin-3 levels may be
confounded by severity of disease in this post-hoc analysis.
It has however been shown before, that chronic use of
diuretics is associated with increases in aldosterone levels.
From our data, we hypothesize that this may be associated
with persistent elevations of galectin-3 as well. Elevated
galectin-3 has been linked to HF development and progres-
sion, but also to development of renal disease. We herein
provide evidence that renal clearance of galectin-3 is impaired
in HF. We captured the potential interactions between
galectin-3, aldosterone, and cardiorenal disease in a hypo-





Figure 4. Repeated analysis in samples from the same patients 6 weeks after baseline assessment.
A, Plasma and urinary galectin-3 at baseline and at 6 weeks. B, Scatterplot of plasma galectin-3 levels
at baseline and at 6 weeks. C, Scatterplot of urinary galectin-3 levels at baseline and at 6 weeks.
D, Galectin-3 excretion rate in controls and chronic heart failure patients at baseline and 6 weeks.
E, Fractional galectin-3 excretion in controls and chronic heart failure patients at baseline and
6 weeks. *P<0.05. NS, non-signiﬁcant.
DOI: 10.1161/JAHA.114.000962 Journal of the American Heart Association 8























This is a relatively small study, and we could not extensively
model the statistical correlations of urine galectin-3. Further-
more, the absolute levels of urine galectin-3 cannot be
compared to other data. We are aware of 1 other report in
prostate cancer patients where urinary galectin-3 levels were
measured. Unfortunately, a different ELISA was used in this
study.36 It is, however, the ﬁrst study that evaluated plasma
and urine galectin-3 in the same patient cohorts. We studied
control subjects, HF patients, and also end-stage renal
disease patients who were on HD, spanning different degrees
of renal (dys)function. There is an imbalance in clinical
characteristics between the 3 different study groups, which
could have led to potential confounding. We made an effort to
fully correct for most potential confounders, but this resulted
in a very small subgroup with limited power.
Perspectives
Renal handling of galectin-3 appears to be different in HF.
Plasma galectin-3 is clearly elevated, while urinary levels are
similar to control subjects. This may be explained by a
Figure 5. Galectin-3 excretion rate in control and CHF patients
stratiﬁed by GFR. Excretion rate of galectin-3 in control subjects
and CHF patients. Stratiﬁcation of the CHF patients was based
upon GFR. CHR indicates chronic heart failure; GFR, glomerular
ﬁltration rate.
Figure 6. Distribution of plasma aldosterone and galectin-3 and
further stratiﬁed by diuretic and nondiuretic users. Displays the
distribution of the heart failure patients based upon plasma
galectin-3 level (percentile) and plasma aldosterone level (per-
centile). The cohort is divided based upon the use of diuretics. As
shown in the upper right quadrant, 45% of the patients on diuretics
are present and only 8% of the patients without diuretics.
Figure 7. Galectin-3 and creatinine levels before and after the
dialyzer. Displayed are the results of the values of galectin-3 and
creatinine before and after the dialyzer. PostHD indicates after
the artiﬁcial kidney; PreHD, prior to the artiﬁcial kidney.
Figure 8. The role of galectin-3 in the cardiorenal syndrome.
Hypothetical scheme showing the possible interactions between
galectin-3 and aldosterone in cardiorenal disease. CKD indicates
chronic kidney disease.
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reduced renal clearance of galectin-3 and a lower fractional
galectin-3 clearance, and this is associated with high
aldosterone levels and the use of diuretics. This is supported
by extremely elevated galectin-3 concentration in HD
patients. We conclude that reduced renal clearance of
galectin-3 in HF patients may explain, in part, the accumu-
lation and increase in plasma galectin-3 in HF. These data
help to explain the observed relation between renal dysfunc-
tion and galectin-3 in HF, but may also provide a novel
mechanism as to why renal dysfunction has detrimental long-
term consequences for HF patients.
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Same analysis in a subset of the cases and controls according to possible confounders (age, gender, diabetes 
mellitus and smoking status).  
Table S1. Galectin-3 Related Parameters: Full population 
Variables HF Patients 
(n = 101) 
Control Subjects 
(n = 20) 
P value 
Plasma Galectin-3, ng/mL 16.6 (14.5-19.3) 9.7 (8.9-12.4) <0.001 
Urinary Galectin-3, ng/mL 28.1 (19.7-49.5) 35.1 (21.2-50.3) 0.830 
Galectin-3 clearance, mL/min 2.3 (1.5-3.4) 3.9 (2.3-6.4) 0.005 
Fractional Galectin-3 excretion, % 2.4 (1.7-3.7) 3.0 (1.9-5.5) 0.018 





Table S2. Galectin-3 Related Parameters: Females excluded 
Variables HF Patients 
(n = 94) 
Control Subjects 
(n = 14) 
P value 
Plasma Galectin-3, ng/mL 16.4 (14.5-19.2) 9.7 (8.7-12.1) <0.001 
Urinary Galectin-3, ng/mL 29.4 (20.6-50.3) 39.7 (22.5-52.3) 0.536 
Galectin-3 clearance, mL/min 2.3 (1.6-3.6) 2.8 (2.0-5.7) 0.021 
Fractional Galectin-3 excretion, % 2.4 (1.7-3.8) 2.9 (1.1-4.9) 0.260 





Table S3. Galectin-3 Related Parameters: DM excluded 
Variables HF Patients 
(n = 87) 
Control Subjects 
(n = 20) 
P value 
Plasma Galectin-3, ng/mL 16.2 (14.4-19.0) 9.7 (8.9-12.4) <0.001 
Urinary Galectin-3, ng/mL 28.1 (19.3-47.6) 35.1 (21.2-50.3) 0.790 
Galectin-3 clearance, mL/min 2.3 (1.5-3.3) 3.9 (2.3-6.4) <0.001 
Fractional Galectin-3 excretion, % 2.4 (1.7-3.5) 3.0 (1.9-5.5) 0.013 








Table S4. Galectin-3 Related Parameters: Smokers excluded 
Variables HF Patients 
(n = 87) 
Control Subjects 
(n = 20) 
P value 
Plasma Galectin-3, ng/mL 16.0 (14.4-19.4) 9.7 (8.9-12.4) <0.001 
Urinary Galectin-3, ng/mL 29.0 (19.0-49.0) 35.1 (21.2-50.3) 0.810 
Galectin-3 clearance, mL/min 2.3 (1.4-3.3) 3.9 (2.3-6.4) 0.002 
Fractional Galectin-3 excretion, % 2.4 (1.7-3.6) 3.0 (1.9-5.5) 0.026 







Table S5. Galectin-3 Related Parameters: Exact age matching 
Variables HF Patients 
(n = 44) 
Control Subjects 
(n = 20) 
P value 
Plasma Galectin-3, ng/mL 15.8 (14.0-19.5) 9.7 (8.9-12.4) <0.001 
Urinary Galectin-3, ng/mL 24.8 (19.7-42.0) 35.1 (21.2-50.3) 0.810 
Galectin-3 clearance, mL/min 2.2 (1.4-3.3) 3.9 (2.3-6.4) 0.004 
Fractional Galectin-3 excretion, % 2.0 (1.5-3.0) 3.0 (1.9-5.5) 0.007 






Table S6. Galectin-3 Related Parameters: Age matched, DM excluded 
Variables HF Patients 
(n = 41) 
Control Subjects 
(n = 20) 
P value 
Plasma Galectin-3, ng/mL 15.8 (13.9-19.3) 9.7 (8.9-12.4) <0.001 
Urinary Galectin-3, ng/mL 24.9 (19.8-41.6) 35.1 (21.2-50.3) 0.418 
Galectin-3 clearance, mL/min 2.3 (1.4-3.3) 3.9 (2.3-6.4) 0.005 
Fractional Galectin-3 excretion, % 2.0 (1.5-3.0) 3.0 (1.9-5.5) 0.009 









Table S7. Galectin-3 Related Parameters: Age matched, DM and Smokers excluded 
Variables HF Patients 
(n = 30) 
Control Subjects 
(n = 20) 
P value 
Plasma Galectin-3, ng/mL 15.7 (13.8-19.5) 9.7 (8.9-12.4) <0.001 
Urinary Galectin-3, ng/mL 28.0 (19.9-41.7) 35.1 (21.2-50.3) 0.616 
Galectin-3 clearance, mL/min 2.3 (1.4-3.6) 3.9 (2.3-6.4) 0.056 
Fractional Galectin-3 excretion, % 2.1 (1.6-3.2) 3.0 (1.9-5.5) 0.035 
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Same analysis in a subset of the cases and controls according to possible confounders (age, gender, diabetes 
mellitus and smoking status).  
Table S1. Galectin-3 Related Parameters: Full population 
Variables HF Patients 
(n = 101) 
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(n = 20) 
P value 
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Galectin-3 clearance, mL/min 2.3 (1.5-3.4) 3.9 (2.3-6.4) 0.005 
Fractional Galectin-3 excretion, % 2.4 (1.7-3.7) 3.0 (1.9-5.5) 0.018 





Table S2. Galectin-3 Related Parameters: Females excluded 
Variables HF Patients 
(n = 94) 
Control Subjects 
(n = 14) 
P value 
Plasma Galectin-3, ng/mL 16.4 (14.5-19.2) 9.7 (8.7-12.1) <0.001 
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Table S4. Galectin-3 Related Parameters: Smokers excluded 
Variables HF Patients 
(n = 87) 
Control Subjects 
(n = 20) 
P value 
Plasma Galectin-3, ng/mL 16.0 (14.4-19.4) 9.7 (8.9-12.4) <0.001 
Urinary Galectin-3, ng/mL 29.0 (19.0-49.0) 35.1 (21.2-50.3) 0.810 
Galectin-3 clearance, mL/min 2.3 (1.4-3.3) 3.9 (2.3-6.4) 0.002 
Fractional Galectin-3 excretion, % 2.4 (1.7-3.6) 3.0 (1.9-5.5) 0.026 







Table S5. Galectin-3 Related Parameters: Exact age matching 
Variables HF Patients 
(n = 44) 
Control Subjects 
(n = 20) 
P value 
Plasma Galectin-3, ng/mL 15.8 (14.0-19.5) 9.7 (8.9-12.4) <0.001 
Urinary Galectin-3, ng/mL 24.8 (19.7-42.0) 35.1 (21.2-50.3) 0.810 
Galectin-3 clearance, mL/min 2.2 (1.4-3.3) 3.9 (2.3-6.4) 0.004 
Fractional Galectin-3 excretion, % 2.0 (1.5-3.0) 3.0 (1.9-5.5) 0.007 






Table S6. Galectin-3 Related Parameters: Age matched, DM excluded 
Variables HF Patients 
(n = 41) 
Control Subjects 
(n = 20) 
P value 
Plasma Galectin-3, ng/mL 15.8 (13.9-19.3) 9.7 (8.9-12.4) <0.001 
Urinary Galectin-3, ng/mL 24.9 (19.8-41.6) 35.1 (21.2-50.3) 0.418 
Galectin-3 clearance, mL/min 2.3 (1.4-3.3) 3.9 (2.3-6.4) 0.005 
Fractional Galectin-3 excretion, % 2.0 (1.5-3.0) 3.0 (1.9-5.5) 0.009 









Table S7. Galectin-3 Related Parameters: Age matched, DM and Smokers excluded 
Variables HF Patients 
(n = 30) 
Control Subjects 
(n = 20) 
P value 
Plasma Galectin-3, ng/mL 15.7 (13.8-19.5) 9.7 (8.9-12.4) <0.001 
Urinary Galectin-3, ng/mL 28.0 (19.9-41.7) 35.1 (21.2-50.3) 0.616 
Galectin-3 clearance, mL/min 2.3 (1.4-3.6) 3.9 (2.3-6.4) 0.056 
Fractional Galectin-3 excretion, % 2.1 (1.6-3.2) 3.0 (1.9-5.5) 0.035 
Median values with (25
th
 to 75
th
 percentile) 
 
 
 
